DOTmed June 3, 2024
Surmodics, a provider of medical device coatings and in vitro diagnostic technologies, announced a definitive agreement to be acquired by GTCR, a prominent private equity firm, for approximately $627 million.
Under the agreement, GTCR affiliates will purchase all outstanding Surmodics shares at $43.00 per share in cash. This acquisition price represents a 41.1% premium over Surmodics’ 30-day volume-weighted average closing price as of May 28, 2024. The Surmodics board of directors has unanimously approved the transaction and recommends that shareholders vote in favor.
“We are pleased to announce this transaction, which enables Surmodics shareholders to realize immediate value creation with a substantial premium, reflecting the significant progress and important achievements made by our employees,” said Gary Maharaj, president and CEO...
Today's Sponsors
Today's Sponsor